Table 3.

Technical, clinical, and safety outcomes.

Outcome	Anterior mean ± SD (N) median (IQR) or % (n/N)	Posterior mean ± SD (N) median (IQR) or % (n/N)	T-test or chi-squared P-value	Adjusted P-value*
mTICI post-procedure (core lab)			<0.001	0.001
0	2.7% (21/780)	2.7% (1/37)
1	0.9% (7/780)	2.7% (1/37)
2a	8.7% (68/780)	5.4% (2/37)
2b	76.4% (596/780)	48.6% (18/37)
3	11.3% (88/780)	40.5% (15/37)
Substantial reperfusion (mTICI 2b/3) (imaging core lab)	87.7% (684/780)	89.2% (33/37)	0.786	0.915
Embolization to new territory	0.9% (7/780)	0.0% (0/37)	0.563	0.362
Categorical mRS at 90 days			0.515	0.484
0	20.6% (177/858)	28.2% (11/39)
1	22.5% (193/858)	20.5% (8/39)
2	12.8% (110/858)	17.9% (7/39)
3	14.1% (121/858)	7.7% (3/39)
4	10.0% (86/858)	5.1% (2/39)
5	4.1% (35/858)	7.7% (3/39)
6	15.9% (136/858)	12.8% (5/39)
Good functional outcome (mRS 0–2) at 90 days	55.9% (480/858)	66.7% (26/39)	0.187	0.207
Excellent outcome (mRS 0–1) at 90 days	43.1% (370/858)	48.7% (19/39)	0.491	0.329
Early neurological improvement: NIHSS reduction ≥8 points or reaching 0–1 at 24 h	54.7% (456/834)	56.8% (21/37)	0.804	0.524
Mortality at 90 days	15.8% (136/861)	12.8% (5/39)	0.617	0.547
Device-related SAE	0.2% (2/932)	0.0% (0/43)	0.761	0.271
Index procedure-related SAE	1.7% (16/932)	0.0% (0/43)	0.386	0.741
sICH at 24 h	1.5% (12/795)	0.0% (0/38)	0.446	0.797
PH-2 at 24 h	2.6% (21/795)	0.0% (0/38)	0.310	0.594

Bold value denotes a statistically significant difference. SD, standard deviation; IQR, interquartile range; mTICI, modified Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SAE, severe adverse event; ICH, intracranial hemorrhage; PH, parenchymal hematoma, sICH, symptomatic intracerebral hemorrhage.

^*P-values are adjusted for age, NIHSS at baseline, gender, time from onset to arrival, and tPA administration. Other outcome variables are shown with unadjusted p-values due to zero or one event in the posterior group making adjusted modeling infeasible.